Download PDF
Thromb Haemost 1992; 68(03): 268-272
DOI: 10.1055/s-0038-1656363
Original Article
Schattauer GmbH Stuttgart

Immunoglobulin Fractions Isolated from Patients with Antiphospholipid Antibodies Prevent the Inactivation of Factor Va by Activated Protein C on Human Endothelial Cells

Montserrat Borrell
1   The Servei d’Hematologia and FISP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Nuria Sala
1   The Servei d’Hematologia and FISP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Conxita de Castellarnau
2   The FISP (Departament d’Aterotrombosi i Biologia Vascular), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Silvia Lopez
2   The FISP (Departament d’Aterotrombosi i Biologia Vascular), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Merce Gari
1   The Servei d’Hematologia and FISP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Jordi Fontcuberta
1   The Servei d’Hematologia and FISP, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 21 January 1991

Accepted after revision 25 March 1992

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We studied the effect of purified immunoglobulins (Ig) from 21 patients with antiphospholipid antibodies (aPL) on factor Va degradation by activated protein C (aPC) on cultured human umbilical vein endothelial cells (HUVEC). Sera from patients were tested on an ELISA aPL assay to determine the isotype with aPL activity. HUVEC were incubated with purified IgG or IgM fraction from controls or patients. Activated PC and factor Va were then added and factor Va degradation was measured after several reaction times. 13 of 14 IgM and 8 of 10 IgG from patients showed an inhibitory effect on factor Va degradation by aPC when compared with control Ig. We also observed the same inhibitory effect with patients’ Ig on studying the degradation of factor Va by aPC in a purified system containing aPC, protein S and phospholipids. These results suggest that aPL antibodies disturb the anticoagulant activity of aPC, which may contribute to the thrombotic tendency of these patients.

 

  • References

  • 1 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
    CrossrefPubMedGoogle Scholar
  • 2 Elias M, Eldor A. Thromboembolism in patients with the “lupus” type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
    CrossrefPubMedGoogle Scholar
  • 3 Bowie JW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
    PubMedGoogle Scholar
  • 4 Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis. Haemostasis 1985; 15: 254-262
    PubMedGoogle Scholar
  • 5 Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980; 2: 366
    PubMedGoogle Scholar
  • 6 Branch WD, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326
    CrossrefPubMedGoogle Scholar
  • 7 Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979; 94: 312-323
    PubMedGoogle Scholar
  • 8 Carreras LO, Machin SJ, Deman R, Defreyn G, Vermylen J et al. Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; i: 244-246
    PubMedGoogle Scholar
  • 9 Comp PC, De Bault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non specific anticoagulants. Blood 1983; 62: 299
    PubMedGoogle Scholar
  • 10 Cariou R, Tobelem G, Belluci S, Soria J, Soria C. et al Effect of lupus anticoagulant and antithrombogenic properties on endothelial cells-inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostas 1988; 60: 54-58
    PubMedGoogle Scholar
  • 11 Freyssinet JM, Cazenave JP. Lupus-like anticoagulants, modulation of the protein C pathway and thrombosis. Thromb Haemostas 1987; 58: 679-681
    PubMedGoogle Scholar
  • 12 Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-Thrombomodulin. J Rheumatol 1990; 17: 785-789
    PubMedGoogle Scholar
  • 13 Kitchen S, Malia RG, Greaves M, Preston FE. Inhibition of protein S cofactor activity by antiphospholipid antibodies. Br J Haematol 1989; 71 Suppl. 1 3
    PubMedGoogle Scholar
  • 14 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432
    PubMedGoogle Scholar
  • 15 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107
    CrossrefPubMedGoogle Scholar
  • 16 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
    CrossrefPubMedGoogle Scholar
  • 17 Caen J, Larrieu MJ, Samama M. L’Hémostase. Méthodes d’exploration et diagnostic practique. 2nd edn. L’Expansion Scientifique Française, Paris: 1975
    Google Scholar
  • 18 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedGoogle Scholar
  • 19 Ewing NP, Kasper CK. In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 1989; 77: 479
    PubMedGoogle Scholar
  • 20 Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6
    CrossrefPubMedGoogle Scholar
  • 21 Esmon NL, Owen WG, Esmon CT. Isolation of a membrane bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-864
    PubMedGoogle Scholar
  • 22 Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63: 671-675
    PubMedGoogle Scholar
  • 23 Gimbrone MA, Shefton EJ, Cruise SA. Isolation and primary culture of endothelial cells from human umbilical vessels. Tissue Culture Assoc 1979; 4: 813-817
    PubMedGoogle Scholar
  • 24 Dejana E, Balconi G, De Castellarnau C, Barbieri B, Vergara M, De Gaetano G. Prostacyclin production by human endothelial and bovine smooth muscle cells in culture. Effect of repeated stimulation with arachidonic acid, thrombin and ionophore A 23187. Biochim Biophys Acta 1983; 750: 261-267
    PubMedGoogle Scholar
  • 25 Broekmans AW, Conard J. Hereditary protein C deficiency. In: Protein C and Related Proteins. Bertina RM. (ed) Churchill Livingstone, London: 1988. pp 160-181
    Google Scholar
  • 26 Briët E, Broekmans AW, Engesser L. Hereditary protein S deficiency. In: Protein C and Related Proteins. Bertina RM. (ed) Churchill Livingstone: London: 1988. pp 203-212
    Google Scholar
  • 27 Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize Protein S. Blood 1986; 67 (4) 1168-71
    PubMedGoogle Scholar
  • 28 Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med 1986; 146: 2153-2159
    CrossrefPubMedGoogle Scholar